Bioblast Pharma (ORPN) Set to Announce Quarterly Earnings on Thursday

Bioblast Pharma (NASDAQ:ORPN) is scheduled to be issuing its quarterly earnings data on Thursday, February 22nd.

Shares of Bioblast Pharma (NASDAQ:ORPN) opened at $2.87 on Thursday. The firm has a market capitalization of $8.92, a price-to-earnings ratio of -1.12 and a beta of 0.37. Bioblast Pharma has a twelve month low of $1.49 and a twelve month high of $6.85.

Separately, ValuEngine upgraded Bioblast Pharma from a “strong sell” rating to a “sell” rating in a report on Friday, December 1st.

COPYRIGHT VIOLATION NOTICE: This piece was published by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at

About Bioblast Pharma

Bioblast Pharma Ltd (BioBlast) is an Israel-based development-stage biopharmaceutical company. The Company is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. It focuses on therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease.

Earnings History for Bioblast Pharma (NASDAQ:ORPN)

Receive News & Ratings for Bioblast Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioblast Pharma and related companies with's FREE daily email newsletter.

Leave a Reply